Global Liquid Biopsy Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Sample Tissue (Blood, Urine, Saliva, Others), By Biomarkers (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (CTDNA), Cell-Free DNA (CFDNA), Extracellular Vesicles (EVs), Others), By Application (Screening, Disease Prognosis, Drug Response and Resistance), And By Geography - Forecasts From 2021 To 2026
- Published : Dec 2021
- Report Code : KSI061611890
- Pages : 120
The global liquid biopsy market is projected to grow at a CAGR of 20.58% to reach US$5,706.095 million by 2026, from US$1,539.615 million in 2019. Liquid biopsy, also known as fluid biopsy, is a non-invasive method that allows for the collection and examination of non-solid biological tissue such as blood to provide a variety of information about a tumour. From a patient's blood sample, medical professionals can learn about numerous features of a tumour using liquid biopsies. The liquid biopsy can be used by doctors to determine which treatments are best for their patients. In the event of patients whose tissue cannot be biopsied or as an addition to thoroughly analysing medication response, liquid biopsies are a helpful alternative to surgical biopsies. These procedures also allow medical practitioners to acquire repeated samples during the treatment process (which is not possible with a Tumor biopsy) to evaluate the tumour's development and medication resistance in the patient. Liquid biopsies have been developed as a result of advancements in sensitive technologies for a variety of clinical applications, including disease detection, monitoring treatment response, patient stratification, and therapy selection, as well as detection of recurrence or the presence of residual disease after surgery.
The growing patient population base due to the increased occurrence of cancer may account for the market's rise. Increasing demand for non-invasive procedures will also help the liquid biopsy market expand during the projected period. Cancer is the biggest cause of mortality in the world, with over 10 million fatalities expected by 2020, in a report stated by World Health Organization (WHO). Although cancer incidence rates remain greatest in more developed locations, death rates in less developed nations are higher due to inadequate access to treatment facilities and a lack of understanding about the benefits of early identification. The most common cancers are lung cancer, colon cancer, breast cancer, and prostate cancer. Among all malignancies, lung cancer is the greatest cause of mortality. Breast cancer is the second most prevalent kind of cancer in the world, and it is also the leading cause of cancer-related deaths among women. Reduced cost, early prognosis, therapy monitoring, identification of tumour heterogeneity, acquired drug resistance, and patient comfort are all advantages of liquid biopsy over standard cancer diagnostics procedures (by eliminating the need for surgery).
Growth Factors
- The rising investments in research and development and the growing technological advancements.
One of the major reasons for the growth of the global liquid biopsy market is the growing technological advancements and the rising investments in their R&D. Increased investment in liquid biopsy research and development are supporting market revenue growth. Due to rapid technological developments and low DNA sequencing costs, CtDNA liquid biopsy is quickly becoming the most popular non-invasive technique for cancer profiling and therapy monitoring applications. Guardant360 CDx, which utilizes liquid biopsy and next-generation sequencing technology to detect patients with certain types of epidermal growth factor receptor (EGFR) gene mutations in a deadly form of metastatic non-small cell lung cancer, received FDA approval in August 2020.
Restraints
- Uncertain regulatory situations for liquid biopsy, as well as negative reimbursement practices, may stifle expansion.
A major restraint in the growth of the global liquid biopsy market is the uncertain regulatory situations for liquid biopsy, as well as negative reimbursement practices. Liquid biopsies are categorized as laboratory-developed testing (LDT). The US Food and Drug Administration has submitted a draught to tighten LDT rules; nevertheless, the LDT regulation is still unclear. Increased FDA rules on LDTs might significantly stifle the expansion of the molecular diagnostics and liquid biopsy industries. This is also likely to raise the price of launching new tests and cause them to be delayed on the market. Also, the lack of desired specificity and sensitivity limits the market growth during the forecast period. In addition to regulatory issues, the liquid biopsy industry has reimbursement issues which will further restrain the market growth of the global liquid biopsy market during the forecast period.
Impact of COVID-19 on the Liquid Biopsy Market
The COVID-19 pandemic has had a great impact on the world as a whole and has led to economic breakdown and loss of life. COVID-19, a coronavirus illness, has spread throughout the world. As a result of the rise in the number of coronavirus patients, governments throughout the world have enacted a slew of regulations and restrictions, stifling market growth in the early stages of the projected period. Early diagnostic initiatives have been halted because of this. Furthermore, there has been a decline in cancer-related screenings, consultations, treatments, and operations, with variations by cancer type and service location globally, leading to a rise in cancer morbidity and death in 2020. The pandemic has also had an influence on the logistics and supply of cancer diagnostic raw materials and components, as well as other critical commodities needed in liquid biopsy manufacturing. During the COVID-19 pandemic, these variables restrict the expansion of the liquid biopsy market.
Competitive Insights
The market leaders for the liquid biopsy market are F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Genomic Health, Inc., Qiagen N.V., NeoGenomics Laboratories, Inc., Biocept, Inc., LungLife AI, Inc., Illumina, Inc., Cardiff Oncology and Guardant Health, Inc.
Global Liquid Biopsy Market Scope:
Report Metric | Details |
Market Size Value in 2019 | US$1,539.615 million |
Market Size Value in 2026 | US$5,706.095 million |
Growth Rate | CAGR of 20.58% from 2019 to 2026 |
Base Year | 2019 |
Forecast Period | 2021–2026 |
Forecast Unit (Value) | USD Million |
Segments Covered | Sample Tissue, Biomarkers, Application, And Geography |
Regions Covered | North America, South America, Europe, Middle East and Africa, Asia Pacific |
Companies Covered | F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Genomic Health, Inc., Qiagen N.V., NeoGenomics Laboratories, Inc., Biocept, Inc., LungLife AI, Inc., Illumina, Inc., Cardiff Oncology, Guardant Health, Inc. |
Customization Scope | Free report customization with purchase |
Segmentation:
- By Sample Tissue
- Blood
- Urine
- Saliva
- Others
- By Biomarkers
- Circulating Tumor Cells (CTCs)
- Circulating Tumor DNA (ctDNA)
- Cell-Free DNA (cfDNA)
- Extracellular Vesicles (EVs)
- Others
- By Application
- Screening
- Disease Prognosis
- Drug Response and Resistance
- By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- UAE
- South Africa
- Others
- Asia Pacific
- Japan
- China
- India
- South Korea
- Indonesia
- Taiwan
- Thailand
- Others
- North America
Frequently Asked Questions (FAQs)
The liquid biopsy market is projected to grow at a CAGR of 20.58% during the forecast period.
Liquid Biopsy Market was valued at US$1,539.615 million in 2019.
The global liquid biopsy market is projected to reach a total market size of US$5,706.095 million by 2026.
The market leaders for the liquid biopsy market are F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., Genomic Health, Inc., Qiagen N.V., and NeoGenomics Laboratories, among others.
One of the major reasons for the growth of the global liquid biopsy market is the growing technological advancements and the rising investments in their R&D.
1.1. Market Overview
1.2. Covid-19 Scenario
1.3. Market Definition
1.4. Market Segmentation
2. Research Methodology
2.1. Research Data
2.2. Assumptions
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of End-Users
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Global Liquid Biopsy Market Analysis, by Sample Tissue
5.1. Introduction
5.2. Blood
5.3. Urine
5.4. Saliva
5.5. Others
6. Global Liquid Biopsy Market Analysis, by Biomarkers
6.1. Introduction
6.2. Circulating Tumor Cells (CTCs)
6.3. Circulating Tumor DNA (ctDNA)
6.4. Cell-Free DNA (cfDNA)
6.5. Extracellular Vesicles (EVs)
6.6. Others
7. Global Liquid Biopsy Market Analysis, by Application
7.1. Introduction
7.2. Screening
7.3. Disease Prognosis
7.4. Drug Response & Resistance
8. Global Liquid Biopsy Market Analysis, by Geography
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. UK
8.4.4. Italy
8.4.5. Spain
8.4.6. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. South Africa
8.5.4. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Taiwan
8.6.6. Thailand
8.6.7. Indonesia
8.6.8. Others
9. Competitive Environment and Analysis
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. Company Profiles
10.1. F. Hoffmann-La Roche AG
10.2. Bio-Rad Laboratories, Inc.
10.3. Genomic Health, Inc.
10.4. Qiagen N.V.
10.5. NeoGenomics Laboratories, Inc.
10.6. Biocept, Inc.
10.7. LungLife AI, Inc.
10.8. Illumina, Inc.
10.9. Cardiff Oncology
10.10. Guardant Health, Inc.
F. Hoffmann-La Roche AG
Bio-Rad Laboratories, Inc.
Genomic Health, Inc.
NeoGenomics Laboratories, Inc.
Biocept, Inc.
LungLife AI, Inc.
Illumina, Inc.
Cardiff Oncology
Guardant Health, Inc.
Related Reports
Report Name | Published Month | Download Sample |
---|---|---|
Cancer Diagnostics Market Size & Share: Industry Report, 2023-2028 | Sep 2023 | |
Biopsy Devices Market Size & Share: Trends, Report, 2021 - 2026 | Jul 2021 | |
Breast Cancer Diagnosis Market Size & Share: Report, 2024-2029 | Apr 2024 | |
Global Cancer Biomarkers Market Insights: Growth, Forecast 2030 | Dec 2024 | |
Breast Cancer Treatment Market Growth: Industry Report, 2019-2024 | May 2021 |